Medical insights
Understanding modern medical weight management
Modern weight-management medicines influence biological pathways involved in appetite, satiety, digestion and metabolism. They are prescription treatments for appropriately assessed patients, not cosmetic shortcuts. Their benefits need to be considered alongside side effects, contraindications, nutritional health, muscle preservation and long-term weight-maintenance planning.
This information is educational and is not an advertisement for a prescription-only medicine. Availability, licensing and suitability may change. Treatment can be considered only after an individual medical assessment.
Evidence explained clearly
Questions patients commonly ask
Each article separates established guidance from emerging research, gives the date the evidence was checked and links to its principal sources.
What are GLP-1 medicines and how do they affect appetite?
GLP-1 is a naturally occurring gut hormone involved in appetite, satiety, digestion and blood-glucose regulation. Medicines that activate the GLP-1 receptor can help some people feel fuller and eat less. Some newer medicines act on additional hormone pathways. They are prescription treatments that require individual assessment, monitoring and discussion of risks.
Read the medical article Clinical explainerWhy medical weight management is more than an injection
An injection may deliver a medicine, but it does not provide diagnosis, risk assessment, nutritional guidance, side-effect management or long-term planning. Safe medical weight management requires a clinician to understand why weight has changed, whether treatment is suitable and how the patient will be monitored.
Read the medical article Fast-changing evidenceWhat is the difference between semaglutide and tirzepatide?
Semaglutide and tirzepatide are prescription-only medicines with different receptor activity. Semaglutide acts at the GLP-1 receptor, while tirzepatide acts at GIP and GLP-1 receptors. Neither should be selected through a simple online comparison: licensing, indication, medical history, tolerability, other medicines and individual response all matter.
Read the medical article Fast-changing evidenceWhat are peptides, and are all peptide therapies evidence-based?
Peptides are short chains of amino acids that can act as signalling molecules in the body. Some peptide-based medicines are rigorously tested, licensed treatments. However, the label “peptide therapy” is also used for unlicensed products whose quality, safety and effectiveness may not have been established.
Read the medical article Fast-changing evidenceAre weight-loss medicines safe?
Licensed weight-management medicines can be safe and effective for appropriately selected patients, but they are not risk-free. Safety depends on choosing a suitable treatment, reviewing medical history and other medicines, increasing doses appropriately, recognising adverse effects and providing continued follow-up.
Read the medical article Clinical explainerCan weight-loss medication affect muscle mass?
Weight loss normally includes some loss of lean tissue as well as fat. The clinical objective should therefore be better health and improved body composition, not simply the lowest possible number on the scales.
Read the medical article Clinical explainerWhy can weight return after stopping weight-management medication?
Weight can return after medication is stopped because biological drivers of appetite and weight regulation can re-emerge. This is not evidence that the patient has failed. A responsible plan should discuss treatment duration, maintenance, food environment, activity, sleep and follow-up before active treatment ends.
Read the medical article Fast-changing evidenceWhat is retatrutide, and is it available in the UK?
Retatrutide is an investigational medicine that acts on three hormone-receptor pathways: GIP, GLP-1 and glucagon. Clinical trials have reported substantial average weight reduction, but trial results do not establish that a medicine is licensed, available or suitable for routine prescribing in the UK.
Read the medical article Fast-changing evidenceWhat weight-loss medicines are being researched next?
Research is exploring dual and triple receptor agonists, amylin combinations, glucagon-containing treatments, oral small molecules, longer-acting medicines and approaches intended to support maintenance. These programmes are investigational unless a current UK marketing authorisation has been confirmed.
Read the medical article Clinical explainerMedical weight management during perimenopause and menopause
Perimenopause and menopause can affect sleep, body composition, appetite, activity, mood and where fat is stored. However, hormonal change is rarely the only factor involved, so weight concerns deserve a broader medical assessment.
Read the medical article